Search - tctmd.com

Displaying 301 - 320 of 2054

Sort: Relevancy | Date

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

News Daily News

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

Yael L. Maxwell

November 03, 2021

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

News Daily News

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

Yael L. Maxwell

November 02, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

News Daily News

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

October 29, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

News Conference News TCT 2021

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

Yael L. Maxwell

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

October 05, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

In Adults, CV Pathology Dominates COVID-19 Multisystem Inflammatory Syndrome

News Daily News

In Adults, CV Pathology Dominates COVID-19 Multisystem Inflammatory Syndrome

September 23, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

News Daily News

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

Michael O'Riordan

September 20, 2021

Long-term Anticoagulation After Unprovoked VTE: New Insights

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

September 13, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.